Sergey Golitsyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2353275/publications.pdf

Version: 2024-02-01

759055 182361 15,258 39 12 51 citations h-index g-index papers 64 64 64 9915 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
2	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	13.9	4,215
3	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 806-817.	13.9	2,207
4	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547
5	The Changing Landscape for StrokeÂPrevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	1.2	244
6	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	1.6	195
7	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
8	COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm, 2015, 12, 1105-1112.	0.3	22
9	Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology, 2018, 14, 664-669.	0.3	20
10	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology, 2021, 17, 193-199.	0.3	15
11	Atrial Appendage Transcriptional Profile in Patients with Atrial Fibrillation with Structural Heart Diseases. Annals of the New York Academy of Sciences, 2006, 1091, 205-217.	1.8	13
12	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology, 2015, 11, 577-581.	0.3	10
13	Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety. Rational Pharmacotherapy in Cardiology, 2019, 14, 826-830.	0.3	10
14	Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter. Journal of Cardiovascular Pharmacology, 2014, 64, 247-255.	0.8	8
15	2020 Clinical practice guidelines for Supraventricular tachycardia in adults. Russian Journal of Cardiology, 2021, 26, 4484.	0.4	8
16	Recent advances in diagnosis and management of atrial fibrillation. Terapevticheskii Arkhiv, 2019, 91, 11-18.	0.2	7
17	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety. Rational Pharmacotherapy in Cardiology, 2021, 17, 668-673.	0.3	7
18	Role of electrocardiographic and echocardiographic types of left bundle branch block in prediction of response to cardiac resynchronization therapy. Terapevticheskii Arkhiv, 2018, 90, 76-83.	0.2	6

#	Article	IF	CITATIONS
19	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
20	Systems Biology and grid technologies: Challenges for understanding complex cell signaling networks. Future Generation Computer Systems, 2007, 23, 428-434.	4.9	5
21	RESULTS OF CONTINUOUS POSITIVE UPPER AIRWAY PRESSURE TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION AND OBSTRUCTIVE SLEEP APNEA. Russian Journal of Cardiology, 2017, , 111-116.	0.4	5
22	The effectiveness of cardiac resynchronization therapy in patients with chronic heart failure of various origin depending on the structural myocardial injury in cardiac magnetic resonance imaging. Russian Journal of Cardiology, 2019, , 22-32.	0.4	4
23	The value of cardiovascular magnetic resonance in myocarditis with different clinical presentation. Terapevticheskii Arkhiv, 2019, 91, 28-36.	0.2	4
24	A case of arrhythmia due to myocarditis treated by antiviral therapy: new diagnostic approaches using peripheral biomarkers. European Heart Journal, 2013, 34, 17-17.	1.0	3
25	Relationship of Focal Fibrosis According to Magnetic Resonance Tomography, Autoantibodies to Cardiac Membrane Receptors and Ventricular Arrhythmias in Patients With Dilated Cardiomyopathy. Kardiologiya, 2014, 12_2014, 29-36.	0.3	3
26	LOCALIZATION OF THE LEFT VENTRICULAR MYOCARDIAL SCARRING AND ITS ELECTRICAL ACTIVATION IN PATIENTS WITH HEART FAILURE AND DIFFERENT RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY. Journal of Arrhythmology, 2020, 26, 5-14.	0.1	2
27	Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation. Terapevticheskii Arkhiv, 2021, 93, 1052-1057.	0.2	2
28	Electrical storm due to myocarditis in post-infarct patient: When two diseases meet. Cor Et Vasa, 2015, 57, e347-e353.	0.1	1
29	Changes in the receptor activity of \hat{l}^2 2-adrenoreceptors of human T-lymphocytes under the effect of \hat{l}^2 2-agonists. Molecular Biology, 2016, 50, 880-886.	0.4	1
30	Solid-phase fragment condensation for synthesis of peptides from the immunodominant sequence of \hat{l}^21 -adrenoreceptor. Russian Journal of Bioorganic Chemistry, 2017, 43, 351-358.	0.3	1
31	Soluble suppression of tumorigenesis-2 (sST2), a new potential biomarker of response to cardiac resynchronization therapy and cardiac contractility modulation in patients with chronic heart failure. Alʹmanah KliniAeskoj Mediciny, 2021, 49, 99-112.	0.2	1
32	Paroxysmal supraventricular tachycardia in patient with dilated cardiomyopathy and concomitant cardiac conduction defects: a case report and discussion. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2368.	0.4	1
33	COMPARISON RESULTS OF THE INTRACARDIAC ELECTROPHYSIOLOGICAL STUDY IN PATIENTS WITH TYPICAL ATRIAL FLUTTER AND FIBRILLATION. Russian Journal of Cardiology, 2017, , 125-131.	0.4	1
34	RESULTS OF NON-INVASIVE ACTIVATION MAPPING OF THE HEART IN "IDIOPATHIC―VENTRICULAR ARRHYTHMIAS IN COMPARISON WITH STRUCTURAL CHARACTERISTICS OF MYOCARDIUM BY MAGNETIC RESONANCE IMAGING. Russian Journal of Cardiology, 2018, , 32-40.	0.4	1
35	Synthetic conformational antigen which simulates the extracellular part of the M2-muscarinic receptor: interaction with blood sera of patients suffering from idiopathic arrhythmias. Russian Journal of Bioorganic Chemistry, 2013, 39, 252-258.	0.3	0
36	Rare Cause of Wide QRS Tachycardia. Case Reports in Cardiology, 2015, 2015, 1-6.	0.1	0

#	Article	IF	CITATIONS
37	Pitfalls in rate and rhythm control: Severe concomitant orthostatic hypotension unmasks after conversion to sinus rhythm. Cor Et Vasa, 2017, 59, e450-e453.	0.1	0
38	Clinical experience of new antiarrhythmic drug refralon for pharmacological cardioversion in patients with atrial fibrillation after pulmonary vein cryoablation. Journal of Arrhythmology, 2021, 28, 55-62.	0.1	0
39	Paroxysmal supraventricular tachycardia in a patient with dilated cardiomyopathy and concomitant cardiac conduction disorders. Clinical case and discussion of the problem. Cardiovascular Therapy and Prevention (Russian Federation), 0, 19, .	0.4	0